68Ga-CXCR4-targeted PET/CT Outperforms 18F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma: Theranostic Insights
Clinical Nuclear Medicine, cilt.51, sa.6, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 6
- Basım Tarihi: 2026
- Doi Numarası: 10.1097/rlu.0000000000006052
- Dergi Adı: Clinical Nuclear Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Anahtar Kelimeler: CXCR4, FDG, PET/CT, granulocytic sarcoma, acute myeloid leukemia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
68Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18F-FDG PET/CT. Compared with 18F-FDG PET/CT, 68Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.